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SUMMARY 
Background 
Rindopepimut, a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of a 
EGFRvIII-specific peptide conjugated to keyhole limpet hemocyanin (KLH). Single-arm studies 
of rindopepimut in patients with newly diagnosed, EGFRvIII+ glioblastoma and minimal 
residual disease (MRD) resulted in median survival of 20-22 months, compared to ~16 months 
for matched contemporary datasets. The ACT IV study was conducted to demonstrate 
prolongation of survival by rindopepimut when added to standard chemotherapy. 
Methods 
This pivotal, randomized, double-blind, phase 3 trial was conducted at 165 hospitals in 22 
countries. Eligible patients had newly diagnosed glioblastoma confirmed to express EGFRvIII by 
central analysis, and had undergone maximal surgical resection and completion of standard 
chemoradiation without progression. Patients were stratified by RPA class, MGMT promoter 
methylation, and geographic region, and randomized (1:1) to receive rindopepimut (500 µg 
admixed with 150 µg GM CSF) or control (100 µg KLH) via monthly intradermal injection until 
progression or intolerance, concurrent with standard temozolomide (150-200 mg/m2 for 5/28 
days) for 6-12 cycles or longer. Patients, investigators, and the trial sponsor were blinded to 
treatment allocation. Randomization and preparation of blinded treatment were managed via 
interactive response technology by designated pharmacists otherwise uninvolved in study 
conduct. Primary endpoint was intention-to-treat analysis of overall survival for MRD patients 
(enhancing tumor <2 cm2 post-chemoradiation by central review) aiming to detect a log-rank 
hazard ratio (HR) ≤0·71 with 80% power and alpha=0·05. The trial is registered with 
ClinicalTrials.gov (NCT01480479). 
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Findings  
Between April 12, 2012 and December 15, 2014, 745 patients were enrolled (405 MRD; 338 
SRD; 2 unevaluable). The study was terminated for futility after a preplanned interim analysis. 
At final analysis, there was no significant difference in overall survival for the MRD (HR 1·01, 
95% CI 0·79-1·30; p=0·93) population. Rindopepimut was well tolerated with robust anti-
EGFRvIII immune response. Most common grade 3-4 adverse events for all 369 treated patients 
in the rindopepimut group vs 372 treated patients in the control group included: 
thrombocytopenia (33 [9%] vs 23 [6%]), fatigue (6 [2%] vs 19 [5%]), brain edema (8 [2%] vs 11 
[3%]), seizure (9 [2%] vs 8 [2%]), and headache (6 [2%] vs 10 [3%]). Serious adverse events 
included seizure (18 [5%] vs 22 [6%]) and brain edema (7 [2%] vs 12 [3%]).  
Interpretation 
Despite consistent rindopepimut-induced humoral responses, rindopepimut did not prolong 
survival in patients with newly diagnostic glioblastoma. Combination approaches potentially 
including rindopepimut may be required to demonstrate efficacy of immunotherapy in 
glioblastoma. 
Funding 
Celldex Therapeutics, Inc.  
 
 5  
 
RESEARCH IN CONTEXT  
 
Evidence before this study 
Using PubMed, we performed a systematic review of the scientific literature published prior to 
August 1, 2011 using the search terms “glioblastoma” and publication type "randomized 
controlled trial" or “clinical trial, phase III”. The standard of care for newly diagnosed 
glioblastoma established in 2005, maximum feasible surgical resection followed by radiotherapy 
and temozolomide chemotherapy, is associated with median overall survival of approximately 15 
months. Despite the introduction of a number of investigational approaches in the subsequent 
years, no treatment had successfully demonstrated further improvement in survival. The addition 
of the search term “EGFRvIII” and expansion of our search to any clinical trial did not identify 
any other agents specifically targeting EGFRvIII. Finally, a search including “glioblastoma”, 
“EGFRvIII” and “survival” produced a few retrospective studies showing similar or worse 
median and long-term survival for patients whose tumor expressed EGFRvIII. Three prior 
studies of rindopepimut had been conducted in patients with newly diagnosed, EGFRvIII-
expressing glioblastoma and minimal residual disease. In these studies, rindopepimut was 
associated with a strong anti-EGFRvIII humoral immune response, marked reduction in 
EGFRvIII expression in available recurrent tumor samples, and a median survival of 20-22 
months, as compared to ~12 months for a small matched contemporary dataset and 15 months 
for the small subset of patients with newly diagnosed EGFRvIII-expressing glioblastoma 
randomized to receive standard of care therapy in the ACT III study.  
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Added value of this study 
To our knowledge, the ACT IV study is the first randomized trial evaluating the efficacy of an 
EGFRvIII-targeted therapy for newly diagnosed glioblastoma. Despite the strong anti-EGFRvIII 
immune response generated in patients, the primary study analysis did not demonstrate a survival 
benefit for patients with minimal residual disease who received rindopepimut with 
temozolomide. A potential long-term survival benefit was observed in exploratory analyses of a 
subset of patients with significant residual disease, which may challenge the view that minimal 
tumor burden is required for immunotherapy to be effective. Also notable is that patients in the 
control group fared markedly better than matched control datasets available at the time of study 
design, suggesting improvement in outcome since the study was originally designed.  
 
Implications of all the available evidence 
These results question the utility of immunotherapy targeting a single tumor antigen with 
heterogeneous tumor expression, as well as the optimal setting for evaluation of immunotherapy. 
Patients with more significant residual disease expressing the target antigen may experience 
greater benefit from generation of targeted immunity than those with completely resected 
disease. Recent data from a randomized, double-blind, phase 2 study in recurrent EGFRvIII 
positive GBM (the ReACT study) suggest a prominent treatment effect (overall survival HR 
0·53, 95% CI 0·32-0·88; p=0·013) for rindopepimut when combined with standard 
bevacizumab. Combination with temozolomide may compromise an immunological effect, in 
contrast with bevacizumab. The results of the ACT IV study also question the predictive value of 
both historical control datasets (matched patients from non-study databases) and small 
randomized phase 2 trial datasets (such as ACT III) for the design of phase 3 studies. These data 
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lend support to further clinical trials utilizing combination strategies such as immunotherapy 
with angiogenesis inhibition.   
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MANUSCRIPT TEXT 
Introduction 
Glioblastoma is the most common malignant primary brain tumor in adults. Its annual incidence 
is > 3 per 100,000 world-wide without major regional variation, and males are affected more 
often than females.1 The standard of care, maximum feasible surgical resection followed by 
radiotherapy with concomitant and maintenance temozolomide chemotherapy 
(TMZ/RT→TMZ), contributes to a median overall survival in the range of 15 months.2,3 
 
The tumor treating fields device, recently reported to extend survival to 20·5 months, represents 
an additional treatment option.4 Treatment at recurrence, which may include second surgery, re-
irradiation, alkylating chemotherapy using nitrosoureas such as lomustine or temozolomide 
rechallenge, or antiangiogenic therapy using bevacizumab, is less well standardized and has not 
demonstrated a significant impact on survival. Poor prognostic factors include low performance 
status, older age, incomplete resection, and an unmethylated promoter of the DNA repair gene, 
O6-methylguanine-DNA methyltransferase (MGMT). Novel treatment approaches to 
glioblastoma are therefore urgently needed, and immunotherapy has now become the major area 
of clinical research. 
 
The epidermal growth factor receptor (EGFR) gene is amplified in more than 40% of 
glioblastomas, and EGFR amplification is frequently associated with a deletion mutation 
affecting exons 2-7, referred to as EGFRvIII or delta-EGFR. EGFRvIII expression occurs in 
approximately 20-30% of all glioblastomas.5-7 The potential immunogenicity of the EGFRvIII 
mutation, first recognized decades ago, resulted in the development of rindopepimut, a peptide 
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vaccine containing the specific novel amino acid sequence created by the EGFRvIII deletion 
mutation conjugated to keyhole limpet hemocyanin (KLH). Rindopepimut has been explored in 
two small single arm phase 2 trials, ACTIVATE and ACT II, as well as a larger phase 2 trial, 
ACT III, which was initially planned as an open-label, randomized, phase 3 trial but was 
converted to a single-arm design following near-complete voluntary attrition of the first 16 
patients randomized to receive temozolomide alone.6,8,9 In these trials, approximately 100 
patients with EGFRvIII-expressing glioblastoma who had received a gross total resection and 
had no evidence of progression after radiotherapy with concomitant temozolomide were treated 
with rindopepimut alone (ACTIVATE) or rindopepimut with adjuvant temozolomide (ACT II, 
ACT III). These three trials resulted in a consistent and encouraging progression-free survival in 
the range of 15 months from diagnosis and overall survival of 24 months from diagnosis, which 
compared favorably with contemporary patient cohorts (appendix, p 7). The selection of patients 
with minimal residual disease (MRD) after completion of chemoradiation was based on the 
assumption that MRD would minimize the tumor-associated immunosuppression typical of 
glioblastoma. ACT IV was designed as a pivotal, randomized, placebo-controlled, phase 3 
clinical trial to demonstrate prolongation of survival by rindopepimut. 
 
Methods 
Study Design and Participants 
The ACT IV study is a randomized, double-blind, controlled study conducted at 165 hospitals in 
22 countries (appendix, p 11). The study was open to men and women ≥18 years of age with 
newly diagnosed EGFRvIII-expressing glioblastoma. Confirmation of glioblastoma histology 
and EGFRvIII expression analysis from resected tissue by real-time polymerase chain reaction 
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(RT-PCR) were performed centrally (LabCorp, Research Triangle Park, NC). Patients must have 
undergone maximal surgical resection and have completed standard radiation (up to 60 Gy) with 
concomitant temozolomide (75 mg/m2 per day).2 In order to be eligible, at least 90% of the 
planned radiotherapy dose had to be delivered. Disease progression during chemoradiation, any 
additional tumor-specific treatment for glioblastoma, inability to taper corticosteroid to ≤2 mg of 
dexamethasone (or equivalent) per day for at least 3 days prior to randomization, Eastern 
Cooperative Oncology Group (ECOG) performance status ≥3 in the week prior to 
randomization, diffuse leptomeningeal disease, gliomatosis cerebri, infratentorial disease, active 
infection, and immunosuppressive disease were exclusionary.  
 
An independent imaging review committee (IRC; BioClinica, Princeton, NJ) evaluated post-
operative and post-chemoradiation brain MRIs, and retrospectively classified patients as having 
either minimal residual disease (MRD; <2 cm2 of residual enhancing tumor on post-
chemoradiation imaging) or significant residual disease (SRD; ≥2 cm2 of residual enhancing 
tumor on post-chemoradiation imaging).  
 
The study was compliant with the Declaration of Helsinki and guidelines on Good Clinical 
Practice. Ethics approval was obtained at all participating centers and all patients provided 
written informed consent. The full trial protocol can be found in the appendix. 
 
Randomization and masking 
Eligible patients were stratified by MGMT promoter methylation status, the European 
Organisation for Research and Treatment of Cancer (EORTC) recursive partitioning analysis 
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(RPA) class,10,11 and geographic region (North America and Western Europe vs. all other 
regions), and randomized to the treatment groups in a 1:1 ratio, using a prespecified 
randomization sequence with a block size of 4. Unblinded pharmacists who were otherwise 
uninvolved in study conduct obtained randomized treatment assignments and managed study 
treatment via interactive response technology. Study treatments were prepared in the pharmacy 
and delivered to study staff in blinded, pre-loaded syringes. KLH was given as a control injection 
to produce a local reaction similar to that expected with rindopepimut in order to maintain the 
treatment blind. 
 
Pharmacovigilance staff at the study sponsor and contract research organization (CRO) received 
treatment assignments for individual patients when necessary to comply with international safety 
reporting. Pharmacy records were audited by an independent team of CRO staff. The study data 
monitoring committee (DMC) and the supportive independent statistical group at the CRO 
viewed unblinded data. All other study staff, patients and investigators remained blinded to 
treatment assignments. 
 
Procedures 
All patients were to receive standard maintenance temozolomide at a dose of 150-200 mg/m2 for 
five of 28 days, for 6-12 cycles,2 or longer if consistent with local standard of care. In addition, 
patients randomized to the rindopepimut group received 500 µg of rindopepimut admixed with 
150 µg GM-CSF (Leukine®, Sanofi-Aventis), while the control group received 100 µg KLH 
(Biosyn, Carlsbad CA). Each 0.8 mL dose was administered as 2-8 separate intradermal 
injections into the skin of the thigh below the groin. The allowance for 2-8 injections allowed for 
smaller volume of individual intradermal injections, potentially reducing patient discomfort and 
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risk of leakage. Experimental treatment was to start 7-14 days after completion of standard 
chemoradiation, and was administered as two initial priming doses (study days 1 and 15), then 
monthly on day 21 of each temozolomide cycle and continuing after the end of maintenance 
temozolomide until disease progression or intolerance. Since all toxicities related to 
rindopepimut vaccination were expected to be immunologically mediated, no adjustment to the 
dose of double-blind vaccine was allowed; however, dose omission or delay was allowed.    
 
Brain MRIs were performed within 14 days after completion of chemoradiation, every 8 weeks 
for six months, every 12 weeks through the second year, every 16 weeks through the fourth year, 
and every 26 weeks thereafter, or until documented disease progression. Tumor response and 
progression were assessed per the Response Assessment in Neuro-Oncology (RANO) Working 
Group criteria,12 with minor modifications for the purpose of protocol standardization (appendix, 
p 8). Local investigator assessments guided individual treatment decisions. The retrospective 
IRC review, blinded to treatment assignment and investigator assessments, was utilized for the 
primary analyses of progression-free survival and objective tumor response rate.  
 
Safety assessments included monthly physical examination, vital signs, routine laboratory 
monitoring (hematology on day 1 and 22 of each cycle, and blood chemistry and urinalysis on 
day 1 of each cycle), and evaluation of adverse events using NCI Common Terminology Criteria 
for Adverse Events (CTCAE) v. 4·0. The M.D. Anderson Symptom Inventory Brain Tumor 
(MDASI-BT) and EORTC Core Quality of Life Questionnaire (QLQ-C30) and Brain Cancer 
Module (BN20) were completed monthly throughout treatment by patients who were fluent in a 
language in which the questionnaires were validated.  
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EGFRvIII expression: Formalin fixed paraffin embedded (FFPE) tumor tissue was analyzed 
centrally. EGFRvIII variant as well as EGFR wild type were determined using a taqman-based 
real-time RT-PCR assay performed on ABI Prism® 7900HT instrument. The fluorescence 
detected was directly proportional to the amount of RNA present and expressed as cycle 
threshold (Ct). A predefined cut off expressed as delta Ct (Ct of EGFRvIII minus Ct of EGFR 
wild type) of ≤11.0 was used to define a sample as positive for EGFRvIII. The threshold, which 
was selected as a conservative cut-off to minimize the possibility of including EGFRvIII 
negative patients, was defined by the delta Ct values of samples from the ACT III study which 
demonstrated unambiguous calls of positive (n=9) or negative (n=10) by corroboration of IHC 
and PCR results, confirmed by reproducibility testing and accuracy verification.   
 
MGMT promoter methylation: FFPE tumor samples were analyzed centrally at LabCorp under 
license from MDx Health (Irvine, CA) by methylation-specific PCR, based on previously 
published methods.13 
 
Humoral responses to the vaccine: Antibody titers were measured by ELISA using microtiter 
plates directly coated with a 14 amino acid peptide, which spans the exon 1-8 junction of EGFR 
and is specific for the EGFRvIII mutant.14 Dilutions of patient plasma were incubated in the 
plates, and the anti-EGFRvIII antibodies were detected with an Fc γ-specific goat anti-human 
F(ab’)2 antibody conjugated to horseradish peroxidase (Jackson ImmunoResearch Labs, West 
Grove, PA) followed by tetra-methylbenzidine substrate. Absorbance was measured at 
wavelength 450 nm. Patient samples were screened and positive samples titered against a plate-
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specific floating cut-point. The antibody titer for patient samples was calculated as the highest 
dilution with an OD value greater than the mean + 3xSD of replicate negative control samples 
run on the same plate. As the starting dilution was 1:100, samples which screened negative are 
reported with titers < 100. For exploratory analyses of survival, patients were retrospectively 
classified according to the trajectory at which anti-EGFRvIII titers developed with rindopepimut 
treatment (slow, moderate or rapid).   
 
HLA analysis: Typing of HLA class I alleles (A and B loci) and HLA class II alleles (-DR locus) 
by serology or DNA-PCR was performed by an ASHI accredited laboratory (ClinImmune Labs; 
Aurora, CO) using buccal swab samples.  
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Outcomes 
The primary study objective was to demonstrate that rindopepimut improves overall survival 
(defined as the time from randomization to death) when administered with standard 
temozolomide to patients with newly diagnosed, EGFRvIII positive glioblastoma and MRD. The 
extent of residual disease (whether MRD or SRD) was retrospectively determined by the central 
IRC. Patients with SRD formed a second exploratory cohort that had not been included in prior 
studies. The primary endpoint was powered and restricted to the MRD patient population. 
Secondary study objectives were to evaluate the effect of rindopepimut on progression-free 
survival (defined as the time from randomization to disease progression or death, whichever 
occurred first), objective tumor response rate (the proportion of patients achieving a confirmed 
complete or partial response per RANO criteria), health-related quality of life (assessed using the 
MDASI-BT, QLQ-C30, and BN20), and EGFRvIII expression, and to further characterize the 
safety profile and overall immunogenicity of rindopepimut in patients with both MRD and SRD.  
 
Statistical Analysis 
Patients classified with MRD by the IRC were included in the “modified” intent-to-treat (mITT) 
population for primary analysis. A total of 283 deaths in the MRD population at the time of the 
final analysis was calculated to provide 80% power to detect a target hazard ratio (HR) of 0·714, 
which corresponded to a 6-month improvement in median survival (from 15 months for control 
to 21 months for rindopepimut). The targeted number of deaths was based on 1-sided log-rank 
test, overall type I error rate of 0·025, and 2 planned interim analyses of overall survival for 
superiority using an O’Brien-Fleming group sequential monitoring plan. Allowing for a 48-
month accrual period and 10% attrition rate, a sample size of 374 MRD patients was expected to 
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result in 283 deaths within 72 months of the first randomized patient. Supportive secondary 
analyses were performed for all randomized patients (ITT). To control the family-wise error rate 
(the probability of making one or more false discoveries when performing multiple hypotheses 
tests), study analyses were to proceed according to a fixed sequence procedure in which the 
primary analysis was completed for the MRD and ITT populations sequentially, followed by the 
secondary endpoint analyses (appendix, p 1). According to this analysis plan, each sequential 
statistical test was to be considered positive only if the previous statistical test was positive. The 
sample size for SRD patients was not prospectively defined, and analysis of this population was 
planned as exploratory. Safety analyses included patients who received at least one dose of study 
treatment.  
 
Overall survival and progression-free survival, including landmark survival rates, were 
summarized using the Kaplan-Meier method. Primary inferential comparisons between treatment 
groups used the log-rank test stratified by MGMT promoter methylation status, adapted RPA 
class, and geographic region. HR were estimated using a stratified Cox proportional hazards 
model (SAS version 9·4). Objective tumor response rate was summarized for all patients with 
measurable, enhancing tumor on post-chemoradiation MRI per IRC assessment (i.e., the 
“response evaluable” population). 
 
For diagnostic purposes, the overall survival proportional hazard assumption was checked by 
comparing the hazard ratios and assessing the significance level of stratification variables from 
stratified and unstratified Cox models. The interactions between the treatment group and 
stratification variables was explored by inclusion of the stratification factors as covariates in the 
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unstratified Cox model. In recognition of the “delayed treatment effect” previously observed 
with other immunotherapies, exploratory analysis using a weighted logrank test was also 
performed.15  
 
Two interim analyses were planned for superiority and futility after 142 and 212 deaths in the 
MRD population, representing 50% and 75% of the events required for final analysis. The study 
was designed with a non-binding approach for efficacy and futility boundaries. Early stopping 
boundaries for superiority according to an O’Brien-Fleming alpha spending were p=0·002 for the 
first interim analysis and p=0·018 for the second interim analysis. The futility analyses were 
based on the observed treatment effect, with HRs of ≥1·1 and >0·9 representing boundaries for 
futility for the two interim analyses. For the first and second interim analyses, respectively, the 
chances of stopping a positive study for futility were 0.5% and 4.6% and the chances of stopping 
a negative study for futility were 29% and 78%. The DMC evaluated the preplanned interim 
analyses. 
 
This study is registered with ClinicalTrials.gov, number NCT01480479.  
 
Role of the Funding Source 
This study was sponsored and funded by Celldex Therapeutics, Inc. The study sponsor designed 
the study in collaboration with the investigators, managed the clinical trial database and 
performed statistical analysis. The corresponding author had full access to all the data in the 
study and had final responsibility for the decision to submit for publication. 
Results 
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A total of 4,652 patients were screened for study eligibility (Figure 1). In the cohort of 4,519 
patients for whom submitted tumor tissue was adequate for EGFRvIII expression analysis, 1,345 
(30%) were determined to have EGFRvIII-expressing tumors. Between April 12, 2012 and 
December 15, 2014, 745 patients with EGFRvIII-expressing tumors were randomized to receive 
rindopepimut (n=371) or control (n=374). Of these, 405 (195 allocated to rindopepimut and 210 
allocated to control) were assigned to the MRD population by central review and included in the 
primary intention-to-treat analysis, while 741 (369 allocated to rindopepimut and 372 allocated 
to control) received study treatment and were included in the safety analyses. 
 
Pretreatment patient and disease characteristics for randomized patients were well balanced 
between treatment groups within each analysis population (Table 1). 
 
At the second preplanned interim analysis conducted upon 212 deaths in the MRD population 
(data cutoff of October 24, 2015), the futility boundary was crossed. The overall survival HR for 
rindopepimut vs control in the MRD population was 0.99, suggesting that rindopepimut was 
unlikely to be found superior to control. The study was therefore prematurely closed, and 
preliminary primary analysis results were released. Additional survival information was obtained 
as patients were discontinued from study, and final analyses were conducted with a data cutoff of 
April 29, 2016. At study closure and final analysis, 523 deaths (254 in the rindopepimut group 
[129 in the MRD population] and 269 in the control group [135 in the MRD population]) and 
546 progression events (267 in the rindopepimut group [141 in the MRD population] and 279 in 
the control group [149 in the MRD population]) had occurred.  
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Overall survival did not differ between the treatment groups for the MRD (HR 1·01, 95% CI 
0·79-1·30; p=0·93) or ITT (HR 0·89, 95% CI 0·75-1·07; p=0·22) populations (Figure 2). 
Median overall survival (in months) for the rindopepimut and control groups, respectively, was 
20·1 (95% CI 18·5-22·1) vs. 20·0 (95% CI 18·1-21·9) in the MRD population, and 17·4 (95% 
CI 16·1-19·4) vs. 17·4 (95% CI 16·2-18·8) in the ITT population. In exploratory analysis of the 
SRD population, overall survival was similar for the treatment groups, with HR of 0·79 (95% CI 
0·61-1·02; p=0·066). Median overall survival was 14·8 months (95% CI 12·8-17·1) for the 
rindopepimut group and 14·1 months (95% CI 12·6-15·7) for the control group. However, a 
possible long-term survival benefit was observed with a two-year survival rate of 30% (95% CI 
23-37) in the rindopepimut group vs. 19% (95% CI 13-26) in the control group (p=0·029). On 
exploratory subgroup analyses (p-values provided for descriptive purposes only), this apparent 
treatment effect appears most pronounced for patients with SRD treated in the United States (HR 
0·70, 95% CI 0·51-0·96; p=0·027), who developed anti-EGFRvIII humoral response at a 
“moderate” rate (HR 0·57, 95% CI 0·39-0·83; p=0·0032), and who received nitrosoureas in the 
post-treatment follow-up period (HR 0·49, 95% CI 0·25-0·97; p=0·038). The interactions of 
geographic region and post-treatment nitrosoureas by treatment effects are not statistically 
significant based on proportional hazard models, however, the study was not designed to test 
interactions. Furthermore, no biologically plausible explanations for these findings were 
identified, and subgroup analyses of the MRD population did not demonstrate similar findings 
(Figure 3). In the group of patients who were classified with SRD by investigator assessment 
(rather than the central reviewer), overall survival was no different between treatment groups 
(HR 0·91, 95% CI 0·71-1·18; p=0·48) and two-year survival rate was 30% (95% CI 23-37) in 
the rindopepimut group vs. 20% (95% CI 14-27) in the control group (p=0·046) (appendix, p 2).  
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On sensitivity analysis, some violations of the proportional hazard assumption were observed in 
various strata. Interactions between the treatment group and stratification variables were also 
explored and none of the interaction terms were significant. The weighted logrank p-values for 
pre-specified weights (r1 = 0, r2 = 1, 2) were 0.93 and 0.88 for the MRD population, 0.081 and 
0.092 for the ITT population, and 0.021 and 0.017 for the SRD population, respectively.  
 
The median duration of adjuvant temozolomide within the MRD population was 5.2 months 
(IQR 3.2 - 10.3) for the rindopepimut group vs. 5.0 months (IQR 3.0 - 10.1) for the control 
group. The median duration of adjuvant temozolomide within the SRD population was 4.1 
months (IQR 2.0 - 7.3) for the rindopepimut group vs. 4.1 months (IQR 2.0 - 6.7) for the control 
group. Anticancer therapies received in the post-treatment follow-up period were also well 
balanced among treatment groups (appendix, p 9). Although there were geographic differences in 
the type of anticancer therapies used after progression (appendix, p 10), with more frequent use 
of nitrosoureas in the European Union and more frequent use of bevacizumab in the United 
States, these regional differences did not appear to account for the geographic variability 
observed within the overall survival analyses (Figure 3).      
 
Progression-free survival was similar for the treatment groups within the MRD (HR 1·01, 95% 
CI 0·80-1·29; p=0·91), ITT (HR 0·94, 95% CI 0·79-1·13; p=0·51) and SRD (HR 0·86, 95% CI 
0·66-1·12; p=0·28) populations (appendix, p 3). Objective tumor response rate for the response-
evaluable population was no different between treatment groups (31 [15%] of 208 [95% CI 10-
21] in the rindopepimut group and 27 [15%] of 184 [95% CI 10-21] in the control group). No 
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statistically significant differences in quality of life measures (appendix, p 4) or requirement for 
corticosteroids (appendix, p 5) were observed among the analysis populations.  
 
Rindopepimut treatment resulted in robust humoral response, with treated patients reaching a 
median peak anti-EGFRvIII antibody titer of 1:25,600 (IQR 3,200 – 204,800). The magnitude of 
response was similar between the MRD and SRD populations (Figure 4). The use of 
corticosteroids did not appear to have a significant impact on the rindopepimut-induced humoral 
immune response (appendix, p 6). However, no consistent correlation between increasingly rapid 
or robust titer response and clinical outcome was observed.   
 
Intensity of tumor EGFRvIII expression (RT-PCR delta CT in the baseline sample as described 
in methods) did not correlate with outcome (Figure 3). In the small subset of patients with 
available post-treatment tumor sample, EGFRvIII expression determined by RT-PCR was lost 
for 21 of 37 (57%) rindopepimut-treated patients and 23 of 39 (59%) patients in the control 
group. Mean anti-EGFRvIII titer was not significantly different between the groups of patients 
with either loss or persistence of tumor EGFRvIII. Elimination of EGRFvIII did not correlate 
with outcome (data not shown).  
 
Correlation analysis of HLA type with outcome was performed for the MRD and SRD 
populations. Although B18, A25, and D11 each correlated with overall survival or progression-
free survival in individual analyses, sample sizes were small, this trend was not observed 
consistently among the analysis populations, and these HLA types would not be predicted to 
bind to the EGFRvIII peptide based on algorithm analysis of the peptide. 
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Rindopepimut was very well tolerated (Table 2). Injection site reactions, consisting chiefly of 
transient grade 1-2 erythema, pruritus, and rash, were experienced by the majority of the patients 
who received rindopepimut (294 [80%] of 369), but were also common in the control group (151 
[41%] of 372). Most common grade 3-4 adverse events for all 369 treated patients in the 
rindopepimut group vs 372 treated patients in the control group included: thrombocytopenia (33 
[9%] vs 23 [6%]), fatigue (6 [2%] vs 19 [5%]), brain edema (8 [2%] vs 11 [3%]), seizure (9 [2%] 
vs 8 [2%]), and headache (6 [2%] vs 10 [3%]). Serious adverse events included seizure (18 [5%] 
vs 22 [6%]) and brain edema (7 [2%] vs 12 [3%]). Of the 523 reported deaths, the majority (427) 
were due to progressive disease (204 [80%] of 254 in the rindopepimut group and 223 [83%] of 
269 in the control group), 80 were due to other/unknown cause (41 [16%] in the rindopepimut 
group and 39 [14%] in the control group), and 16 were due to adverse events (9 [4%] in the 
rindopepimut group and 7 [3%] in the control group). One fatal event, a pulmonary embolism 
experienced by a 64-year old male patient after 11 months of treatment, was assessed as 
potentially related to rindopepimut. Eight patients discontinued double-blind vaccine due to 
treatment-related toxicity. These included two cases of hypersensitivity/allergic reaction, two 
cases of rash, and single cases of bone/muscle pain and the fatal pulmonary thromboembolism in 
the rindopepimut group, and single cases of rash and depression in the control group. Despite the 
observation of hypersensitivity reaction attributed to rindopepimut in prior studies,6,8,9 such 
events were infrequent in both treatment groups. There was similarly no evidence for increased 
toxicity that might theoretically arise due to rindopepimut-induced immune infiltration of the 
brain, such as cerebral edema or seizure.   
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Discussion 
The primary analysis of the ACT IV study did not demonstrate a survival benefit for patients 
with MRD who received rindopepimut with temozolomide. The outcome for patients treated 
with rindopepimut was similar to that observed in prior uncontrolled studies. Of note, the 
definition for MRD was increased to <2 cm2 in the ACT IV study, as compared to ≤1 cm2 in 
prior studies. Median overall survival from randomization for MRD patients treated with 
rindopepimut in ACT IV was 20·1 months, which is consistent with the range of 20-22 months 
observed in prior trials in the same population.6,8,9 However, patients in the control group fared 
markedly better than matched control datasets available at the time of study design (appendix, p 
7).  
 
Given the prior ACT III study experience where voluntary attrition of patients randomized to the 
open-label control group rendered the original randomized design infeasible, it was recognized 
that a truly blinded design would be critical for ACT IV. Therefore, rather than an inactive 
placebo, KLH was used as a control injection in order to replicate the local reactions (erythema, 
pruritus and rash) experienced by nearly all patients who receive rindopepimut. KLH can 
generate immune activation and one might speculate that the better-than-expected outcome in the 
control group might result from the generation of an effective immune response unrelated to 
EGFRvIII. However, it is generally thought that a tumor-specific response triggered by KLH 
would require topical application to the tumor itself (intratumoral injection in this case) and that 
a real therapeutic effect is unlikely to result from peripheral intradermal injection. In a small 
phase 2 trial of patients with recurrent disease (ReACT), the same KLH control was utilized with 
control group outcome no better than expected.16 It is also possible that the unexpectedly 
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favorable outcome for the ACT IV control group may result from enrollment of patients at lower 
risk as compared to prior trials. However, the eligibility criteria and baseline characteristics of 
patients in the ACT IV study were similar to the prior phase II studies of rindopepimut. As well, 
ACT IV was a large, global phase III study, where outcomes are generally expected to be less 
favorable than phase II studies restricted to specialized centers. It is more likely that optimization 
of standards of care has promoted improvements in outcome over time,17 as illustrated in 
appendix, p 7. 
 
In light of the negative result for the primary analysis and in accordance with the study’s 
sequential analysis plan, all subsequent analyses should be considered exploratory and cannot be 
interpreted as conclusive. However, the potential long-term survival benefit observed in patients 
with SRD is an interesting result that deserves examination. No imbalances were found that 
might have accounted for this signal of differential activity. Baseline prognostic characteristics, 
corticosteroid dosing, and subsequent therapies were well balanced between both treatment 
groups. Yet, this apparent treatment effect in the SRD population was not consistent across 
geographic regions, the effect was less pronounced when tumor burden was defined by the 
investigator as opposed to central review, and the magnitude of humoral immune response did 
not consistently correlate with presumed treatment benefit or extent of residual disease. Although 
further study would be required to confirm this potential signal, this observation may challenge 
the view that minimal tumor burden is required for immunotherapy to be most effective.  
 
Interestingly, rindopepimut was associated with a survival advantage (HR 0·53, 95% CI 0·32-
0·88; p=0·013) when combined with bevacizumab in ReACT, where per study design patients 
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were not required to have MRD.16 While humoral responses were similar in patients in the ACT 
IV study regardless of the amount of residual tumor present, it is unclear whether there were 
effective cellular responses in these patients. Perhaps residual disease, which would be 
associated with greater EGFRvIII expression, is required to generate effective and persistent 
cellular immunity required for a therapeutic effect. It is also possible that the choice of 
combination therapy may account for what appears to be a more prominent treatment effect in 
the ReACT study, as compared to the smaller, more delayed effect suggested by the SRD 
population in ACT IV. VEGF is known to depress tumor immunity and bevacizumab has been 
shown to enhance immune-mediated antitumor effect in nonclinical models.18 On the other hand, 
temozolomide induced-lymphopenia may reduce the efficacy of an immunotherapy. However, 
this concept is not supported by the ACT II study, in which patients who received dose-
intensified temozolomide with rindopepimut developed more robust EGFRvIII-specific humoral 
immune response despite more significant lymphopenia.  
 
An unexpected observation was the loss of EGFRvIII expression in approximately 60% of the 
small subset of patients with tumor tissue available at recurrence, regardless of study treatment 
received. Loss of EGFRvIII expression has previously been reported to occur in the majority of 
rindopepimut-treated patients,6,8,9 but not in patients receiving standard of care chemoradiation.19 
However, contemporary data sets are contradictory. One RNA only-based study reported 
frequent loss of EGFRvIII expression with standard therapy,20 but this was not confirmed in a 
recent study of the German Glioma Network.5 Although ACT IV screening was performed by 
PCR while the prior studies utilized IHC, the methods have previously demonstrated good 
concordance.6 Supposing that the true rate of EGFRvIII loss at recurrence approaches 50%, one 
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might conclude that the survival benefit observed in the ReACT trial is derived from only half of 
the patients, and would therefore probably be quite significant in a cohort with confirmed 
EGFRvIII expression. More importantly, these data suggest that at least a biopsy is required to 
verify EGFRvIII positivity before patients with recurrent glioblastoma are enrolled into future 
trials targeting this mutation. Yet, the ACT IV results, as well as the lack of stability of 
EGFRvIII and its expression pattern limited to subpopulations of tumor cells5,21 raise questions 
about its role as a molecular target for therapy in primary glioblastoma. Ongoing trials with other 
agents in patients with EGFRvIII-mutated tumors may provide additional insight/clarity in the 
future. 
 
To our knowledge, ACT IV was the most comprehensive study of patients with EGFRvIII-
expressing glioblastoma conducted to date. A total of 4,652 patients were screened for study 
eligibility to achieve 745 randomized patients, and 600 patients with EGFRvIII+ glioblastoma 
were not enrolled. Reasons for failure to enroll are available for 304 of these patients (Figure 1). 
Nearly half declined study participation, likely due in part to the nature of the screening process 
which allowed for an abbreviated “tissue screening” consent, followed later by the formal study 
evaluation and consenting process. The remainder did not meet the strict eligibility criteria for 
the trial, which were intended to duplicate the results observed in prior trials and to maximize the 
chances of achieving a successful result.  
 
Limitations of the study include uncertainties on the significance of the cut-off of EGFRvIII 
expression for inclusion, and the fact that, due to practical considerations related to patient 
accrual, the vaccine was started after radiotherapy rather than as early as possible. Furthermore, 
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whether concurrent chemotherapy with temozolomide blunts potential activity of 
immunotherapy remains controversial. There are some old and some new lessons to be learned 
from the disappointing outcome of ACT IV: Even carefully assembled historical controls may be 
misleading and unsuitable for clinical trial designs, since it is difficult to control for patient 
selection. Even biologically matching data of EGFRvIII loss at progression on anti-EGFRvIII 
treatment need controls. Since the humoral response to EGFRvIII was similar to that observed in 
previous studies of rindopepimut, the present study does not support these responses as a reliable 
predictor of outcome and calls for intensified efforts to establish cellular immune responses as a 
read-out. The selection of one molecular target of immunotherapy might be insufficient, 
especially if its expression is not stable and not ubiquitous, and multipeptide vaccines against 
multiple targets and non-peptides with higher immunogenicity may turn out to be superior. 
Moreover, it would appear most promising to combine a glioma-specific stimulus based on well-
defined antigens with a general activation of the immune system. At present, this seems to be 
most easily achieved with checkpoint inhibition or with the neutralization of strong 
immunosuppressive factors such as TGF-β. Taken together, the results of the ACT IV and 
ReACT trials support the design of innovative clinical trials evaluating combination approaches 
to demonstrate efficacy of immunotherapy in glioblastoma.  
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Go, No-Go decision making for phase 3 clinical trials: Act IV rindopepimut revisited – 
Authors' reply 
 
We appreciate not only the interest of Dr. Nguyen and colleagues in the ACT IV trial, but 
also the thoughtful commentary by Dr. Gerstner.1 From the perspective of several years’ 
additional experience with clinical trial conduct in newly diagnosed glioblastoma relative to the 
time when ACT IV was designed, we feel that the failure to adequately estimate efficacy with a 
new treatment based on historical controls (even when matched for eligibility) provides a good 
lesson to be learned. 
Alternative explanations for the failure of ACT IV may be discussed, but are less compelling. 
Nguyen and colleagues question whether the adjustment to the definition of minimal residual 
disease (from 1 cm2 in prior studies to 2 cm2 in ACT IV, supported by a central expert review in 
which some ACT III patients were retrospectively classified with more significant residual 
disease) contributed to the failure of the study. Although patients with more significant residual 
disease were originally not thought to be the best candidates for vaccination because of 
immunosuppression associated with tumor load, the ACT IV results showed a possible long-term 
survival benefit with rindopepimut for patients with, as opposed to without, more significant 
residual tumor, which suggests that the change in eligibility would not explain the negative result 
for the minimal residual disease population. Furthermore, data on the prognostic value of gross 
total resection are only indirectly relevant to ACT IV since tumor burden in ACT IV was not 
assessed after surgery, but after completion of concomitant chemoradiotherapy; as well, these 
data may not accurately reflect outcome for a population with EGFRvIII expressing tumors. 
Additional factors discussed by both Dr. Gerstner and Dr. Nguyen and colleagues, such as the 
potential insufficiency of targeting a single tumour antigen with heterogeneous tumour 
expression and possibility for temozolomide-induced lymphopenia to limit the efficacy of 
rindopepimut, provide important considerations for the conduct of future immunotherapy trials. 
In addition, accumulating evidence not only from ACT IV indicates that EGFR amplification, 
but not EGFRvIII mutation, is a stable molecular marker throughout the course of disease.2,3  
Ultimately, however, these factors were applicable to the phase II trials of rindopepimut that 
were interpreted as positive and led to the decision to proceed with a phase III trial. In 
conclusion, a significant lesson learned from ACT IV is that even carefully assembled historical 
controls can be misleading and an unsuitable basis for clinical trial designs. As noted by Nguyen 
and colleagues, even larger randomized phase II studies may not accurately predict outcomes, as 
seen in the BELOB experience. Obtaining contemporary outcomes data to standard therapies is 
challenging and remains an important issue especially with the increasing trend for seamless 
oncology-drug development and acceleration of drug development timelines.4, 5 
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TABLES  
 
Table 1. Baseline Patient and Disease Characteristics  
 
MRD Population 
(Primary Analysis Population) 
ITT Population  
(All Randomized Patients) 
SRD Population 
 
 
Rindopepimut 
+ TMZ 
(n=195) 
Control  
+ TMZ 
(n=210) 
Rindopepimut 
+ TMZ 
(n=371) 
Control  
+ TMZ 
(n=374) 
Rindopepimut  
+ TMZ 
(n=175) 
Control  
+ TMZ 
(n=163) 
Age, years (median [IQR]) 
≥65 years (n [%]) 
59 (51-64) 
46 (24%) 
57 (51-64) 
50 (24%) 
59 (51-64) 
87 (23%) 
58 (52-64) 
87 (23%) 
58 (51-64) 
40 (23%) 
59 (52-64) 
37 (23%) 
Male (n [%]) 133 (68%) 121 (58%) 252 (68%) 228 (61%) 118 (67%) 106 (65%) 
ECOG PS (n [%])  0 
 1 
 2 
100 (51%) 
86 (44%) 
9 (5%) 
102 (49%) 
97 (46%) 
11 (5%) 
165 (45%) 
188 (51%) 
18 (5%) 
168 (45%) 
185 (50%) 
21 (6%) 
65 (37%) 
101 (58%) 
9 (5%) 
65 (40%) 
88 (54%) 
10 (6%) 
MGMT promoter (n [%])  Methylated 
 Unmethylated 
 Unknown 
69 (35%) 
107 (55%) 
19 (10%) 
73 (35%) 
119 (57%) 
18 (9%) 
124 (33%) 
224 (60%) 
23 (6%) 
130 (35%) 
218 (58%) 
26 (7%) 
55 (31%) 
116 (66%) 
4 (2%) 
57 (35%) 
98 (60%) 
8 (5%) 
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MRD Population 
(Primary Analysis Population) 
ITT Population  
(All Randomized Patients) 
SRD Population 
 
 
Rindopepimut 
+ TMZ 
(n=195) 
Control  
+ TMZ 
(n=210) 
Rindopepimut 
+ TMZ 
(n=371) 
Control  
+ TMZ 
(n=374) 
Rindopepimut  
+ TMZ 
(n=175) 
Control  
+ TMZ 
(n=163) 
RPA Class (n [%])  III 
 IV 
 V 
25 (13%) 
139 (71%) 
31 (16%) 
27 (13%) 
157 (75%) 
26 (12%) 
46 (12%) 
256 (69%) 
69 (19%) 
37 (10%) 
274 (73%) 
63 (17%) 
21 (12%) 
116 (66%) 
38 (22%) 
9 (6%) 
117 (72%) 
37 (23%) 
Time from diagnosis to randomization, 
months (median [IQR]) 
2.8 (2.6-3.1) 2.8 (2.6-3.1) 2.9 (2.6-3.2) 2.8 (2.6-3.1) 2.9 (2.7-3.2) 2.9 (2.7-3.2) 
Prior radiotherapy dose, Gy (median [IQR]) 60 (60-60) 60 (60-60) 60 (60-60) 60 (60-60) 60 (60-60) 60 (60-60) 
Prior temozolomide dose, mg/m2 (median 
[IQR]) 
3225 
(3150-3300) 
3225 
(3150- 3375) 
3225 
(3150-3300) 
3225 
(3150-3375) 
3225 
(3150-3375) 
3225 
(3150-3375) 
ITT, intention-to-treat; CRT, chemoradiation; ECOG PS; Eastern Cooperative Oncology Group performance status; MGMT, O6-methylguanine-
DNA methyltransferase; MRD, minimal residual disease; NE, not evaluable; RPA, recursive partitioning analysis; SRD, significant residual 
disease  
 36  
 
Table 2. Toxicity 
  Rindopepimut + TMZ Control + TMZ 
  (n=369) (n=372) 
  Grade 1-2 Grade 3 Grade 4 Grade 5 Grade 1-2 Grade 3 Grade 4 Grade 5 
Any adverse event 203 (55%) 110 (30%) 42 (11%) 7 (2%) 187 (50%) 124 (33%) 35 (9%) 7 (2%) 
Injection site reaction 294 (80%) 0   0   0   151 (41%) 0   0   0   
Fatigue 133 (36%) 6 (2%) 0   0   125 (34%) 19 (5%) 0   0   
Nausea 128 (35%) 3 (1%) 0   0   132 (36%) 5 (1%) 0   0   
Headache 122 (33%) 5 (1%) 1 (0.3%) 0   107 (29%) 10 (3%) 0   0   
Thrombocytopenia 66 (18%) 21 (6%) 11 (3%) 0   75 (20%) 14 (4%) 9 (2%) 0   
Constipation 86 (23%) 3 (1%) 0   0   91 (25%) 3 (1%) 0   0   
Vomiting 75 (20%) 2 (1%) 0   0   76 (20%) 4 (1%) 0   0   
Decreased appetite 67 (18%) 4 (1%) 0   0   78 (21%) 1 (0.3%) 0   0   
Dizziness 56 (15%) 2 (1%) 0   0   69 (19%) 2 (1%) 0   0   
Seizure 48 (13%) 7 (2%) 2 (1%) 0   61 (16%) 7 (2%) 1 (0.3%) 0   
Insomnia 55 (15%) 1 (0.3%) 0   0   48 (13%) 0   0   0   
Rash 43 (12%) 3 (1%) 0   0   68 (18%) 5 (1%) 0   0   
Neutropenia 27 (7%) 12 (3%) 7 (2%) 0   16 (4%) 9 (2%) 8 (2%) 0   
Lymphopenia 26 (7%) 17 (5%) 2 (1%) 0   24 (6%) 9 (2%) 3 (1%) 0   
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  Rindopepimut + TMZ Control + TMZ 
  (n=369) (n=372) 
  Grade 1-2 Grade 3 Grade 4 Grade 5 Grade 1-2 Grade 3 Grade 4 Grade 5 
Muscular weakness 39 (11%) 5 (1%) 0   0   39 (11%) 12 (3%) 0   0   
Diarrhea 43 (12%) 0   0   0   64 (17%) 0   0   0   
Depression 36 (10%) 4 (1%) 0   0   47 (13%) 2 (1%) 1 (0.3%) 0   
Back pain 35 (10%) 2 (1%) 0   0   38 (10%) 3 (1%) 0   0   
Edema peripheral 33 (9%) 2 (1%) 0   0   43 (12%) 0   0   0   
Pruritus 34 (9%) 0   0   0   55 (15%) 1 (0.3%) 0   0   
Aphasia 28 (8%) 4 (1%) 2 (1%) 0   41 (11%) 11 (3%) 0   0   
Anxiety 31 (8%) 1 (0.3%) 0   0   44 (12%) 0   0   0   
Gait disturbance 28 (8%) 2 (1%) 0   0   36 (10%) 5 (1%) 0   0   
Arthralgia 30 (8%) 0   0   0   46 (12%) 1 (0.3%) 0   0   
Pyrexia 23 (6%) 1 (0.3%) 0   0   37 (10%) 0   0   0   
Brain edema 9 (2%) 3 (1%) 5 (1%) 0   9 (2%) 4 (1%) 7 (2%) 0   
Hypersensitivity 7 (2%) 1 (0.3%) 0   0   5 (1%) 0   0   0   
Other nervous system disorders 145 (39%) 33 (9%) 4 (1%) 2 (1%) 175 (47%) 32 (9%) 1 (0.3%) 2 (1%) 
Infections and infestations 117 (32%) 19 (5%) 3 (1%) 0   130 (35%) 21 (6%) 2 (1%) 1 (0.3%) 
Respiratory, thoracic and mediastinal 
disorders 
89 (24%) 7 (2%) 4 (1%) 3 (1%) 96 (26%) 5 (1%) 3 (1%) 0   
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  Rindopepimut + TMZ Control + TMZ 
  (n=369) (n=372) 
  Grade 1-2 Grade 3 Grade 4 Grade 5 Grade 1-2 Grade 3 Grade 4 Grade 5 
Other gastrointestinal disorders 85 (23%) 6 (2%) 1 (0.3%) 1 (0.3%) 89 (24%) 10 (3%) 0   0   
Other musculoskeletal and 
connective tissue disorders 
89 (24%) 3 (1%) 0   0   96 (26%) 8 (2%) 0   0   
Other investigations 68 (18%) 14 (4%) 3 (1%) 0   85 (23%) 9 (2%) 3 (1%) 0   
Other general disorders and 
administration site 
conditions 
73 (20%) 8 (2%) 0   0   80 (22%) 13 (3%) 0   2 (1%) 
Injury, poisoning and procedural 
complications 
67 (18%) 8 (2%) 1 (0.3%) 1 (0.3%) 69 (19%) 9 (2%) 1 (0.3%) 0   
Other psychiatric disorders 64 (17%) 9 (2%) 1 (0.3%) 0   64 (17%) 8 (2%) 1 (0.3%) 1 (0.3%) 
Other skin and subcutaneous tissue 
disorders 
72 (20%) 1 (0.3%) 1 (0.3%) 0   95 (26%) 2 (1%) 0   0   
Other metabolism and nutrition 
disorders 
45 (12%) 17 (5%) 3 (1%) 0   56 (15%) 15 (4%) 3 (1%) 0   
Eye disorders 60 (16%) 2 (1%) 0   0   70 (19%) 4 (1%) 0   0   
Renal and urinary disorders 50 (14%) 6 (2%) 1 (0.3%) 0   59 (16%) 5 (1%) 0   0   
Vascular disorders 37 (10%) 9 (2%) 4 (1%) 0   40 (11%) 14 (4%) 2 (1%) 0   
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  Rindopepimut + TMZ Control + TMZ 
  (n=369) (n=372) 
  Grade 1-2 Grade 3 Grade 4 Grade 5 Grade 1-2 Grade 3 Grade 4 Grade 5 
Other blood and lymphatic system 
disorders 
34 (9%) 6 (2%) 3 (1%) 0   29 (8%) 6 (2%) 2 (1%) 1 (0.3%) 
Ear and labyrinth disorders 32 (9%) 2 (1%) 0   0   45 (12%) 0   0   0   
Cardiac disorders 14 (4%) 3 (1%) 1 (0.3%) 1 (0.3%) 19 (5%) 0   1 (0.3%) 2 (1%) 
Reproductive system and breast 
disorders 
16 (4%) 2 (1%) 0   0   14 (4%) 0   0   0   
Endocrine disorders 10 (3%) 2 (1%) 0   0   18 (5%) 1 (0.3%) 0   0   
Neoplasms  11 (3%) 0   0   0   6 (2%) 2 (1%) 1 (0.3%) 0   
Hepatobiliary disorders 0   1 (0.3%) 0   0   3 (1%) 4 (1%) 0   0   
Data are presented for the safety population (all patients who received at least one dose of study treatment, regardless of tumor burden). Table 
shows all grade 1–2 events occurring in ≥ 10% of patients in either group and all grade 3-5 events.  
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FIGURES 
 
 
Figure 1. Trial Profile 
 
 
Figure 2. Overall Survival 
Overall survival in the MRD (primary analysis) population (A), the ITT population (B), and the SRD population (C).  
 
 
Figure 3. Subgroup analyses of overall survival  
 
 
Figure 4. Humoral Response 
Humoral response over time are shown for the MRD and SRD populations within the ACT IV study, along with results from the ACT 
III trial in which 65 patients with newly diagnosed glioblastoma were treated with rindopepimut in addition to temozolomide, and the 
ReACT trial in which 35 patients with recurrent glioblastoma were treated with rindopepimut in addition to standard bevacizumab and 
37 patients were treated with keyhole limpet hemocyanin as control along with bevacizumab.  
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due to study closure
162 discontinued treatment 
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4 adverse events
7 withdrew consent 
4 investigator decision
4 other
1 did not receive treatment 
(discontinued follow-up)
* Reasons for failure to enroll were collected via hard copy screening log, with data for 304 of these 600 patients compiled electronically at the time of study closure. Of these, 143 (47%) declined study participation, 68 (22%) experienced 
progression prior to study entry, 21 (7%) had a contraindicated concurrent illness or low performance status, 11 (4%) did not receive adequate or standard chemoradiation, 11 (4%) were not candidates for adjuvant temozolomide, 10 (3%) 
were receiving exclusionary doses of corticosteroid, and 40 (13%) were not enrolled for other miscellaneous reasons.
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Number at risk (censored)
Rindopepimut+TMZ 195 (0) 190 (0) 150 (3) 102 (12) 42 (39) 21 (50) 7 (61) 4 (62) 0 (66)
Control+TMZ 210 (0) 210 (3) 169 (6) 101 (24) 53 (41) 21 (62) 7 (69) 4 (71) 0 (75)
Number at risk (censored)
Rindopepimut+TMZ 371 (0) 345 (1) 261 (5) 159 (25) 72 (68) 32 (92) 12 (108) 7 (111) 0 (117)
Control+TMZ 374 (0) 347 (3) 268 (7) 149 (35) 73 (61) 25 (90) 8 (98) 4 (101) 0 (105)
Number at risk (censored)
Rindopepimut+TMZ 175 (0) 155 (1) 111 (2) 57 (13) 30 (29) 11 (42) 5 (47) 3 (49) 0 (51)
Control+TMZ 163 (0) 145 (0) 98 (1) 47 (11) 19 (20) 4 (27) 1 (28) 0 (29) 0 (29)
Median (Mo) (95% CI)
Rindopepimut+TMZ 20.1 (18.5, 22.1) 
Control+TMZ 20.0 (18.1, 21.9)
HR (95% CI):  1.01 (0.79, 1.30); p=0.93
Median (Mo) (95% CI)
Rindopepimut+TMZ 17.4 (16.1, 19.4) 
Control+TMZ 17.4 (16.2, 18.8)
HR (95% CI): 0.89 (0.75, 1.07); p=0.22
Median (Mo) (95% CI)
Rindopepimut+TMZ 14.8 (12.8, 17.1) 
Control+TMZ 14.1 (12.6, 15.7)
HR (95% CI):  0.79 (0.61, 1.02); p=0.066
A
B
C
* The fluorescence detected was directly proportional to the amount of RNA present and expressed as cycle threshold (Ct). EGFRvIII intensity is defined by delta Ct (Ct of EGFRvIII - Ct of EGFR wild type). 
** Humoral response is classified according to the trajectory at which anti-EGFRvIII titers developed with rindopepimut treatment.  HR is calculated for the rindopepimut-treated patients within each classification versus 
all patients in the control group.  
Favors Rindopepimut Favors TMZFavors Rindopepimut Favors TMZ
MRD Population SRD Population
Rindopepimut
(events/pts)
Control
(events/pts)
HR (95% CI) P value Rindopepimut
(events/pts)
Control
(events/pts)
HR (95% CI) P value
Overall 129/195 135/210 1.01 (0.79, 1.30) 0.92 124/175 134/163 0.79 (0.61, 1.02) 0.066
Country
USA 76/120 86/133 1.02 (0.75, 1.41) 0.89 78/111 85/100 0.70 (0.51, 0.96) 0.027
Other 53/75 49/77 1.00 (0.65, 1.54) 0.99 46/64 49/63 1.07 (0.68, 1.70) 0.76
Age
<65 98/149 99/160 0.97 (0.72, 1.31) 0.86 93/135 100/126 0.82 (0.61, 1.11) 0.20
≥65 3146 36/50 1.21 (0.71, 2.06) 0.48 31/40 34/37 0.68 (0.39, 1.19) 0.18
Gender
Male 88/133 79/121 1.01 (0.73, 1.39) 0.97 87/118 89/106 0.81 (0.59, 1.12) 0.20
Female 41/62 56/89 0.93 (0.59, 1.44) 0.73 37/57 45/57 0.77 (0.48, 1.23) 0.27
Race
White 115/176 123/193 1.02 (0.78, 1.33) 0.89 111/155 121/144 0.80 (0.61, 1.05) 0.11
Other 14/19 12/17 0.79 (0.24, 2.57) 0.69 13/20 13/19 1.07 (0.32, 3.56) 0.91
MGMT
Methylated 31/69 33/73 1.00 (0.59, 1.68) 1.0 26/55 37/57 0.68 (0.40, 1.15) 0.15
Unmethylated 83/107 92/119 1.05 (0.77, 1.42) 0.78 95/116 89/98 0.84 (0.62, 1.13) 0.25
RPA class
III 10/25 17/27 0.65 (0.28, 1.49) 0.30 14/21 6/9 0.55 (0.19, 1.53) 0.24
IV 97/139 98/157 1.05 (0.79, 1.40) 0.72 82/116 94/117 0.80 (0.59, 1.08) 0.14
V 22/31 20/26 1.11 (0.54, 2.29) 0.77 28/38 34/37 0.83 (0.49, 1.40) 0.49
EGFRvIII intensity*
≤ 0.5 52/76 38/64 0.98 (0.61, 1.57) 0.94 44/63 42/51 0.87 (0.55, 1.38) 0.55
0.5 – 4.24 40/61 52/76 0.89 (0.56, 1.43) 0.64 39/60 37/47 0.81 (0.50, 1.31) 0.39
>4.24 37/58 45/70 1.19 (0.73, 1.92) 0.49 41/52 55/65 0.92 (0.58, 1.46) 0.73
Humoral response**
Slow 23/30 135/210 1.02 (0.64, 1.64) 0.93 33/40 134/163 1.10 (0.73, 1.66) 0.65
Moderate 73/109 135/210 1.09 (0.81, 1.47) 0.56 39/62 134/163 0.57 (0.39, 0.83) 0.0032
Rapid 20/31 135/210 0.69 (0.41, 1.19) 0.18 24/28 134/163 1.01 (0.63, 1.63) 0.96
Subsequent therapy
Reresection 45/59 39/51 1.13 (0.70, 1.82) 0.61 17/26 23/31 0.66 (0.31, 1.44) 0.29
Bevacizumab 73/91 74/94 1.12 (0.79, 1.59) 0.54 61/77 71/78 0.81 (0.56, 1.17) 0.27
Nitrosourea 34/40 39/51 1.07 (0.62, 1.85) 0.81 29/41 23/26 0.49 (0.25, 0.97) 0.038
Temozolomide 29/36 28/40 1.05 (0.56, 1.94) 0.89 22/30 34/39 0.90 (0.46, 1.75) 0.76
Other chemotherapy 26/34 28/31 0.60 (0.32, 1.15) 0.12 15/20 15/17 1.66 (0.61, 4.51) 0.31
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WEB EXTRA MATERIAL 
 
 
Figure 1. Fixed sequence procedure. Fixed sequence procedure was used to control the family wise error rate for 
the primary endpoint and secondary endpoints. Each statistical test was to be considered positive only if the previous 
statistical test was positive. At each analysis (interim or final), the same alpha would be passed from the primary OS 
(mITT) analysis. 
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Figure 2. Overall Survival for Populations Selected by Investigator Assessment  
Overall survival in the population of patients with MRD by investigator assessment (A) and with SRD by 
investigator assessment (B).   
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Number at risk (censored)
Rindopepimut+TMZ 195 (0) 185 (1) 145 (4) 92 (16) 42 (39) 18 (54) 5 (64) 3 (64) 0 (67)
Control+TMZ 196 (0) 188 (2) 153 (5) 91 (19) 51 (34) 20 (53) 6 (58) 3 (60) 0 (63)
Number at risk (censored)
Rindopepimut+TMZ 174 (0) 158 (0) 114 (1) 66 (9) 30 (28) 14 (37) 7 (43) 4 (46) 0 (49)
Control+TMZ 177 (0) 158 (1) 114 (2) 57 (16) 22 (26) 5 (36) 2 (39) 1 (40) 0 (41)
Median (Mo) (95% CI)
Rindopepimut+TMZ 19.5 (17.0, 22.1) 
Control+TMZ 19.2 (17.0, 21.4)
HR (95% CI):  0.99 (0.77, 1.28); p=0.94
Median (Mo) (95% CI)
Rindopepimut+TMZ 16.1 (13.0, 17.8) 
Control+TMZ 15.6 (13.7, 17.5)
HR (95% CI):  0.91 (0.71, 1.18); p=0.48
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Figure 3. Progression-Free Survival 
Progression-free survival in the MRD (primary analysis) population (A), the ITT population (B), and the SRD 
population (C).  
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Number at risk (censored) 
Rindopepimut+TMZ 195 (0) 103 (19) 53 (23) 20 (39) 9 (47) 3 (52) 1 (54) 0 (54) 0 (54)
Control+TMZ 210 (0) 103 (24) 49 (36) 24 (48) 10 (55) 5 (58) 2 (60) 1 (61) 0 (61)
A
Number at risk (censored)
Rindopepimut+TMZ 371 (0) 159 (51) 77 (63) 30 (85) 16 (94) 4 (101) 1 (104) 0 (104) 0 (104)
Control+TMZ 374 (0) 151 (42) 70 (63) 32 (78) 14 (86) 6 (91) 2 (94) 1 (95) 0 (95)
B
Number at risk (censored)
Rindopepimut+TMZ 175 (0) 56 (31) 24 (39) 10 (45) 7 (46) 1 (48) 0 (49)
Control+TMZ 163 (0) 48 (17) 21 (26) 8 (29) 4 (30) 1 (32) 0 (33)
C
Median, mos (95% CI)
Rindopepimut+TMZ 8.0 (7.1, 8.5) 
Control+TMZ 7.4 (6.0, 8.7)
HR (95% CI): 1.01 (0.80, 1.29); p=0.91
Median (Mo) (95% CI)
Rindopepimut+TMZ 7.1 (5.4, 7.9) 
Control+TMZ 5.6 (5.1, 7.1)
HR (95% CI): 0.94 (0.79, 1.13); p=0.51
Median (Mo) (95% CI)
Rindopepimut+TMZ 3.7 (3.5, 5.8) 
Control+TMZ 3.7 (3.3, 4.9)
HR (95% CI): 0.86 (0.66, 1.12); p=0.28
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Figure 4.  Quality of Life  
EORTC QLQ-C30 Global Health Status over time for patients with evaluable data in the MRD (primary analysis) 
population (rindopepimut group, n=194; control group, n=202) (A) and the SRD population (rindopepimut group, 
n=170; control group, n=157) (B).  
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Figure 5.  Corticosteroid Use 
Corticosteroid dose over time for patients receiving corticosteroids at baseline in the MRD (primary analysis) 
population (rindopepimut group, n=57; control group, n=68) (A) and the SRD population (rindopepimut group, 
n=72; control group, n=78) (B).  Median dose (mg), as well as the 25th and 75th percentiles, are shown.  
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Figure 6. Humoral Response 
Humoral response over time are shown for the MRD and SRD populations within the ACT IV study, along with 
results from the ACT III trial in which 65 patients with newly diagnosed glioblastoma were treated with 
rindopepimut in addition to temozolomide, and the ReACT trial in which 35 patients with recurrent glioblastoma 
were treated with rindopepimut in addition to standard bevacizumab and 37 patients were treated with keyhole 
limpet hemocyanin as control along with bevacizumab.  
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Figure 7.  Corticosteroid Use and Anti-EGFRvIII titer 
Geometric mean titer for rindopepimut-treated patients is displayed according to corticosteroid dosing during the 
first eight weeks of study.  Patients are divided into groups who received no corticosteroids, an average daily dose of 
less than 2 mg/kg dexamethasone equivalent, and an average daily dose of more than 2 mg/kg dexamethasone 
equivalent.  
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Table 1. Outcomes for Newly Diagnosed Glioblastoma, by EGFRvIII Expression Status 
 Clinical Trial Median OS from 
study 
randomization 
Median OS 
from diagnosis* 
% EGFRvIII+ % GTR 
Datasets available for ACT IV design 
    
M.D. Anderson “matched” cohort (n=17)1  NA 15.0 100% 100% 
ACT III Controls (n=16)** 15.6 19.1 100% 100% 
TMZ/RT → TMZ (n=287)2  14.6 15.8 NR 39% 
Datasets generated subsequently 
    
RTOG 05253 (Data on File, Celldex)  
Standard dose TMZ (n=411) 
EGFRvIII+ subset (n=62) 
EGFRvIII+ subset matched for ACT III/IV eligibility (n=29) 
Dose-dense TMZ (n=422) 
All EGFRvIII+ patients (n=142) 
 
16.6 
14.2 
16.0 
14.9 
15.1 
 
~19.6 
~17.2 
~19.0 
~17.9 
~16.3 
 
NR 
100% 
100% 
NR 
100% 
 
56% 
NR 
100% 
52% 
NR 
AVAglio trial (n=463)4  16.7 ~18.0 NR 42% 
RTOG 0825 (n=317)5  16.1 ~19.1 NR 59% 
Novocure EF-14 Study (n=229)6 16.6 ~20.4 NR 64% 
German Glioma Network7  
EGFRvIII+ subset matched for ACT III/IV eligibility (n=85) 
NA 21.7 100% 100% 
NA, Not applicable; NR, Not reported 
* Median OS from diagnosis is estimated based upon timing of randomization. 
** Data on file, Celldex. Majority dropped out of trial to receive alternate (unknown) therapies with death 
information reported when available from public records. Eight patients were reported to have died, while the 
remaining patients were followed on study for a range of 0 to 3.3 months before study withdrawal.  
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Table 2. Study-Specific Modifications to RANO Criteria  
Criteria Study-Specific Modification 
General Corticosteroid dose assessed as the average dose 
over the seven (7) days prior to the current scan, as 
compared to the average dose over the 
seven (7) days prior to the baseline scan 
Complete Response: requires all of the following: 
• Complete disappearance of all enhancing measurable and non-measurable disease 
sustained for at least 4 weeks. 
• No new lesions. 
• Stable or improved non-enhancing (T2/FLAIR) lesions 
• Patients must be off corticosteroids (or on physiologic replacement doses only) 
• Stable or improved clinically. 
Patients with non-measurable disease only cannot have a CR; the best response possible is 
SD. 
Physiologic replacement doses of corticosteroids 
defined as: up to the equivalent of 20 mg/day of 
hydrocortisone  
 
Partial Response: requires all of the following: 
• ≥ 50% decrease compared with Baseline in the SPD of all measurable enhancing 
lesions sustained for at least 4 weeks. 
• No progression of non-measurable disease. 
• No new lesions. 
• Stable or improved non-enhancing (T2/FLAIR) lesions on same or lower dose of 
corticosteroids compared with Baseline scan. 
• The corticosteroids dose at the time of the scan evaluation should be no greater than 
the dose at the time of the baseline scan. 
• Stable or improved clinically. 
Patients with non-measurable disease only cannot have a PR; the best response possible is 
SD. 
In order to qualify for Partial Response, subjects 
must be on a corticosteroid dose that is stable 
(< 10% increase) or decreased when compared 
with the dose at the time of the baseline scan. 
 
Stable Disease: requires all of the following: 
• Does not qualify for CR, PR or PD. 
• Stable non-enhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids 
compared with baseline scan. 
• In the event that the corticosteroid dose was increased for new symptoms and signs 
without confirmation of disease progression on neuroimaging, and subsequent follow-
up imaging shows that this increase in corticosteroids was required because of disease 
progression, the last scan considered to show stable disease will be the scan obtained 
when the corticosteroid dose was equivalent to the baseline dose. 
In order to qualify for Partial Response, subjects 
must be on a corticosteroid that is < 50% increased 
when compared with the dose at the time of the 
baseline scan.  
Progressive Disease: defined by any of the following: 
• ≥ 25% increase in SPD of enhancing lesions compared with the smallest (nadir) 
tumor measurement obtained either at baseline (if no decrease) or best response. 
• On stable or increasing doses of corticosteroids. 
• Significant increase in T2/FLAIR nonenhancing lesion on stable or increasing doses 
of corticosteroids compared with baseline scan or best response after initiation of 
therapy not caused by co-morbid events (e.g., radiation therapy, demyelination, 
ischemic injury, infection, seizures, post-operative changes, or other treatment 
effects) 
• Any new lesion. 
• Clear clinical deterioration not attributable to other causes apart from the tumor (e.g., 
seizures, medication adverse effects, complications of therapy, cerebrovascular 
events, infection and so on) or changes in corticosteroid dose. 
• Failure to return for evaluation as a result of death or deteriorating condition. 
• Clear progression of non-measurable disease. 
For subjects with little to no residual disease, a 
25% increase in area could reflect only imaging 
variance. As such, to be considered PD, a > 5 mm 
increase in the sum of the longest diameters of the 
target lesions, along with a ≥ 25% increase in the 
sum of the products of the diameters of the target 
lesions, will be required to call PD. 
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Table 3. Additional therapies received in the post-treatment follow-up period, by analysis population  
 
MRD Population 
(Primary Analysis Population) 
ITT Population  
(All Randomized Patients) 
SRD Population 
 
Rindopepimut+TMZ  
(n=195) 
Control+ 
TMZ  
(n=210) 
Rindopepimut+ 
TMZ  
(n=371) 
Control+ 
TMZ 
(n=374) 
Rindopepimut+ 
TMZ 
(n=175) 
Control+ 
TMZ 
(n=163) 
Radiotherapy/Radiosurgery 14% 18% 13% 14% 11% 9% 
Reresection 30% 24% 23% 22% 15% 19% 
Other anticancer therapy 62% 63% 62% 66% 61% 69% 
Bevacizumab 47% 45% 45% 46% 44% 48% 
Nitrosureas 21% 24% 22% 21% 23% 16% 
Temozolomide 19% 19% 18% 21% 17% 24% 
Other chemotherapy 17% 15% 15% 13% 11% 10% 
Investigational drug 11% 11% 10% 10% 9% 8% 
Tumor-treating fields 4% 4% 4% 3% 5% 2% 
Tyrosine kinase inhibitor 3% 4% 2% 3% 1% 1% 
Check-point inhibitor 2% 2% 2% 2% 2% 1% 
CRT, Chemoradiation; KLH, Keyhole limpet hemocyanin; MRD, Minimal residual disease; SRD, Significant residual disease; TMZ, Temozolomide; NE, Not evaluable  
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Table 4. Additional therapies received in the post-treatment follow-up period, by geographic region 
 MRD Population  SRD Population  
USA (n=253) Canada (n=32) 
EU  
(n=61) 
Other 
(n=59) 
Total 
(n=405) USA (n=211) 
Canada 
(n=38) EU (n=47) 
Other 
(n=42) 
Total 
(n=338) 
Radiotherapy/Radiosurgery 18% 9% 10% 15% 16% 10% 5% 13% 12% 10% 
Reresection 30% 9% 8% 46% 27% 17% 21% 9% 24% 17% 
Other anticancer therapy 63% 66% 62% 61% 63% 67% 68% 57% 60% 65% 
Bevacizumab 52% 25% 41% 36% 46% 54% 29% 36% 31% 46% 
Nitrosureas 21% 16% 31% 25% 23% 19% 16% 38% 10% 20% 
Temozolomide 13% 50% 15% 32% 19% 17% 40% 13% 29% 20% 
Other chemotherapy 13% 13% 18% 29% 16% 9% 8% 13% 21% 11% 
Investigational drug 14% 0 7% 9% 11% 12% 0 0 7% 9% 
Tumor-treating fields 5% 0 2% 0 4% 5% 3% 0 0 1% 
Tyrosine kinase inhibitor 5% 0 0 2% 3% 2% 0 0 0 1% 
Check-point inhibitor 2% 0 3% 3% 2% 2% 0 2% 2% 2% 
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List of Investigators and Trial Sites 
CDX110-04 ACT IV Participating Sites (Institution (Country) Investigator [# Patients]) 
University of California, San Francisco (USA) Dr. Nicholas Butowski [28] 
Washington University School of Medicine (USA) Dr. Jian Campian [24] 
Stanford Cancer Institute (USA) Dr. Lawrence Recht [20] 
Johns Hopkins University (USA) Dr. Michael Lim [15] 
Barrow Neurological Institute (USA) Dr. Lynn Ashby [15] 
University of Pittsburgh Medical Center - UPMC Cancer Centers (USA) Dr. Jan Drappatz [14] 
Juravinski Cancer Centre (CA) Dr. Hal Hirte [15] 
Columbia University Medical Center (USA) Dr. Fabio Iwamoto [13] 
Dent Neurosciences Research Center (USA) Dr. Laszlo Mechtler [12] 
John Theurer Cancer Center at Hackensack University Medical Center (USA) Dr. Samuel Goldlust [12] 
Yale University (USA) Dr. Kevin Becker [11] 
Cleveland Clinic Foundation  (USA) Dr. Gene Barnett [11] 
The Ottawa Hospital Cancer Center (CA) Dr. Garth Nicholas [11] 
The Preston Robert Tisch Brain Tumor Center at Duke (USA) Dr. Annick Desjardins [10] 
Swedish Neuroscience Institute (USA) Dr. Tara Benkers [10] 
University of Southern California/Norris Comprehensive Cancer Center  (USA) Dr. Naveed Wagle [10] 
Texas Oncology (USA) Dr. Morris Groves [10] 
Moores UCSD Cancer Center (USA) Dr. Santosh Kesari [10] 
Debreceni Egyetem Orvos- és Egészségtudományi Centrum Onkológiai Klinika (HU) Dr. Zsolt Horvath [10] 
NorthShore University HealthSystem (USA) Dr. Ryan Merrell [9] 
University of Cincinnati Physicians Corporation  (USA) Dr. Richard  Curry [9] 
University of Pennsylvania  (USA) Dr. James; O'Rourke David Schuster [9] 
Westmead Hospital (AU) Dr. Mark Wong [9] 
University of Washington (USA) Dr. Maciej Mrugala [8] 
University of Utah Department of Neurosurgery (USA) Dr. Randy  Jensen [8] 
Virginia Piper Cancer Institute at Abbott Northwestern Hospital (USA) Dr. John Trusheim [8] 
Wake Forest University Health Sciences Medical Center (USA) Dr. Glenn Lesser [8] 
Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame (CA) Dr. Karl Belanger [8] 
University Hospitals, Case Medical Center (Cleveland) (USA) Dr. Andrew Sloan [7] 
University of Virginia Healthcare System (USA) Dr. Benjamin Purow [7] 
Baylor Research Institute (USA) Dr. Karen Fink [7] 
Northwestern University; Robert H. Lurie Comprehensive Cancer Center (USA) Dr. Jeffrey Raizer [7] 
North Shore University Hospital (USA) Dr. Michael Schulder [7] 
Lehigh Valley Physician Group-Hematology-Oncology Associates (USA) Dr. Suresh Nair [7] 
Kaiser Permanente - Redwood City (USA) Dr. Scott Peak [7] 
Odette Cancer Centre, Sunnybrook HSC (CA) Dr. James Perry [7] 
Ospedale Bellaria (IT) Dr. Alba Brandes [7] 
Department of Neurology, University Hospital Zurich (CH) Dr. Michael Weller [7] 
University of Rochester Medical Center (USA) Dr. Nimish Mohile [6] 
New Jersey Neuroscience Institute (USA) Dr. Joseph Landolfi [6] 
Mary Bird Perkins Cancer Center (USA) Dr. Jon Olson [6] 
Fondazione IRCCS Istituto Neurologico Carlo Besta (IT) Dr. Gaetano  Finocchiaro [6] 
Epworth Healthcare (AU) Dr. Ross Jennens [6] 
Liverpool Hospital (AU) Dr. Paul DeSouza [6] 
Christchurch Hospital (NZ) Dr. Bridget Robinson [6] 
Providence Portland Medical Center (USA) Dr. Marka Crittenden [5] 
Sarah Cannon Research Institute  (USA) Dr. Kent Shih [5] 
Hartford Hospital (USA) Dr. Alexandra Flowers [5] 
University of Arkansas for Medical Sciences (USA) Dr. Shirley Ong [5] 
Froedtert and The Medical College of Wisconsin (USA) Dr. Jennifer Connelly [5] 
Winship Cancer Institute, Emory University School of Medicine (USA) Dr. Costas Hadjipanayis [5] 
Ohio State University (USA) Dr. Pierre Giglio [5] 
Georgia Regents University (USA) Dr. Frank Mott [5] 
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CHUS Hopital Fleurimont (CA) Dr. David Mathieu [5] 
CHUQ, L'Hotel-Dieu de Quebec (CA) Dr. Nathalie Lessard [5] 
Hospital Universitario 12 De Octubre (ES) Dr. Sanchez Juan Sepulveda [5] 
Országos Onkológiai Intézet (HU) Dr. József Lövey [5] 
Royal North Shore Hospital, St. Leonards (AU) Dr. Helen Wheeler [5] 
Royal Brisbane & Women's Hospital (RBWH) (AU) Dr. Po-Ling Inglis [5] 
Palmerston North Hospital  (NZ) Dr. Claire Hardie [5] 
Chao Family Comp Cancer Center (USA) Dr. Daniela Bota [4] 
University of Chicago (USA) Dr. Maciej Lesniak [4] 
City of Hope Cancer Center (USA) Dr. Jana Portnow [4] 
Medical University of South Carolina (USA) Dr. Bruce Frankel [4] 
University of Michigan Health System (USA) Dr. Larry Junck [4] 
Vanderbilt University Medical Center (USA) Dr. Reid Thompson [4] 
Tampa General Hospital (USA) Dr. Lawrence Berk [4] 
British Columbia Cancer Agency - Vancouver Island Centre (CA) Dr. John McGhie [4] 
London Regional Cancer Program (CA) Dr. David Macdonald [4] 
Royal Marsden NHS Foundation Trust (UK) Dr. Frank Saran [4] 
Azienda Ospedaliera San Giovanni Battista Di Torino-Universita Di Torino (IT) Dr. Riccardo Soffietti [4] 
Tel Aviv Sourasky Medical Center (IL) Dr. Deborah Blumenthal [4] 
Real e Benemerita Associação Portuguesa de Beneficiência (BR) Dr. Sá Barreto Costa Marcos André de [4] 
Sir Charles Gairdner Hospital (AU) Dr. Anna Nowak [4] 
Royal Adelaide Hospital (RAH)- The University of Adelaide (AU) Dr. Nimit Singhal [4] 
Centre Hospitalier Universitaire Vaudois CHUV (CH) Dr. Andreas Hottinger [4] 
Inselspital (CH) Dr. Andrea Schmid [4] 
Edward W. Sparrow Hospital Association - Sparrow Regional Cancer Center (USA) Dr. Gordan Srkalovic [3] 
The Methodist Neurological Institute (USA) Dr. David  Baskin [3] 
Dartmouth Hitchcock Medical Center (USA) Dr. Camilo Fadul [3] 
University of Alabama at Birmingham (USA) Dr. Louis Nabors [3] 
Norton Cancer Institute (USA) Dr. Renato LaRocca [3] 
University of Kentucky (USA) Dr. John Villano [3] 
Rush University Medical Center (USA) Dr. Nina Paleologos [3] 
Montreal Neurological Institute and Hospital (CA) Dr. Petr Kavan [3] 
Univeristy of Manitoba-CancerCare Manitoba (CA) Dr. Marshall Pitz [3] 
British Columbia Cancer Agency - Vancouver Centre (CA) Dr. Brian Thiessen [3] 
La Pitié Salpétrière AP-HP (FR) Dr. Ahmed Idbaih [3] 
Institut de Cancerologie de l’Ouest (ICO) - Centre Rene Gauducheau (FR) Dr. Jean Sébastien Frenel [3] 
Institut Gustave Roussy (FR) Dr. Julien Domont [3] 
Universitaetsklinikum Muenster (DE) Dr. Oliver Grauer [3] 
Universitaetskliniken Regensburg (DE) Dr. Peter Hau [3] 
Medical University Vienna - General Hospital (AT) Dr. Christine Marosi [3] 
Na Homolce Hospital (CZ) Dr. Jan Sroubek [3] 
Prince of Wales Hospital (AU) Dr. Elizabeth Hovey [3] 
HCG - Bangalore Institute of Oncology (IN) Dr. P.S. Sridhar [3] 
Austin Hospital (AU) Dr. Lawrence Cher [3] 
University of Florida (USA) Dr. Erin Dunbar [2] 
SUNY Upstate Medical University (USA) Dr. Thomas Coyle [2] 
Allegheny General Hospital (USA) Dr. Jane Raymond [2] 
Loyola University Medical Center (USA) Dr. Kevin Barton [2] 
Helen F Graham Cancer Center  (USA) Dr. Michael Guarino [2] 
Monmouth Cancer Center (USA) Dr. Sumul Raval [2] 
University of Arizona (USA) Dr. Baldassarre Stea [2] 
Massachusetts General Hospital (DFCI affiliate) (USA) Dr. Jorge Dietrich [2] 
Unv Hospitals Bristol NHS Foundation Trust - Bristol Haematology & Onc Ctr (UK) Dr. Kirsten Hopkins [2] 
Western General Hospital (UK) Dr. Sara Erridge [2] 
Klinikum Der J.W. Goethe Universitaet (DE) Dr. Joachim-Peter Steinbach [2] 
Hospital Clinic i Provincial Servicio de Oncología Escalera 2, 5ª planta. (ES) Dr. Losada Estela Pineda [2] 
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ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia) (ES) Dr. Quintero Carmen Balana [2] 
ICO Girona - Hospital Doctor Josep Trueta (Institut Catala D'Oncologia) (ES) Dr. Barco Berron Sonia del [2] 
Vas Megyei Markusovszky Lajos Általános Rehabilitációs és Gyógyfürdo Kórház (HU) Dr. Miklós Wenczl [2] 
Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház (HU) Dr. Katalin Molnár [2] 
Szegedi Tudományegyetem Onkoterápiás Klinika (HU) Dr. Katalin Hideghéty [2] 
Gaffin Center for Neuro-Oncology, Hadassah Hebrew University Medical Center (IL) Dr. Alexander Lossos [2] 
Vrije Universiteit Medisch Centrum (NL) Dr. Linde Myra van [2] 
Fundação Antônio Prudente - Hosptial A.C. Camargo  (BR) Dr.  Ana Levy [2] 
Royal Hobart Hospital (AU) Dr. Rosemary Harrup [2] 
Calvary North Adelaide Hospital (AU) Dr. William Patterson [2] 
Mater Adult Hospital (AU) Dr. Zarnie Lwin [2] 
Siriraj Hospital (TH) Dr. Sith Sathornsumetee [2] 
National Cheng Kung University Hospital (TW) Dr. E-Jian Lee [2] 
Kaohsiung Chang Gung Memorial Hospital (CGMHKS) (TW) Dr. Jih-Tsun Ho [2] 
Fletcher Allen Health Care (USA) Dr. Steven Emmons [1] 
The Long Island Brain Tumor Center at Neurological Surgery, P.C. (USA) Dr. J. Paul Duic [1] 
Legacy Health (USA) Dr. Spencer Shao [1] 
New York Methodist Hospital (USA) Dr. Hani Ashamalla [1] 
Temple University Hospital (USA) Dr. Michael Weaver [1] 
Mt. Sinai Medical Center / Comprehensive Cancer Center (USA) Dr. Jose Lutzky [1] 
Orlando Health, Inc. (USA) Dr. Nicholas Avgeropoulos [1] 
The University of Tennessee Medical Center (USA) Dr. Wahid Hanna [1] 
Covenant Clinic/Iowa Spine and Brain Institute (USA) Dr. Mukund Nadipuram [1] 
Sutter Health-Alta Bates Medical Center (USA) Dr. Gary Cecchi [1] 
UC Davis Cancer Center (USA) Dr. Robert O'Donnell [1] 
Weill Cornell Medical Center (USA) Dr. Susan Pannullo [1] 
Kaiser Permanente Hawaii - Moanalua Medical Center (USA) Dr. Jennifer Carney [1] 
Foothills Hospital Medical Centre (CA) Dr. Mark Hamilton [1] 
QE II Health Science Centre (CA) Dr. Mary MacNeil [1] 
Guy's and St Thomas' NHS - St Thomas Hospital (UK) Dr. Ronald Beaney [1] 
CRLC  VAL D'AURELLE  (FR) Dr. Michel Fabbro [1] 
Klinikum Grosshadern Ludwig-Maximilians Univ. Muenchen (DE) Dr. Oliver Schnell [1] 
Universitaet Erlangen-Nurnberg (DE) Dr. Rainer Fietkau [1] 
Medical University Innsbruck (AT) Dr. Guenther Stockhammer [1] 
Faculty Hospital V Motole (CZ) Dr. Bela Malinova [1] 
Multiscan, s.r.o., Pardubice (CZ) Dr. Karel Odrazka [1] 
Masaryk´s  Hospital Usti nad Labem (CZ) Dr. Martin Sames [1] 
ICO L’Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia) (ES) Dr. Gil Miguel Gil [1] 
3rd Department of Medical-Oncology, "Hygeia" Hospital (GR) Dr. Evangelia Razis [1] 
Soroka University Medical Center (IL) Dr. Konstantin  Lavrenkov [1] 
Grupo Médico Camino S.C.  (MX) Dr. Guillermo Castro [1] 
Antiguo Hospital Civil de Guadalajara (MX) Dr. Francisco Ramirez [1] 
Coordenação de Pesquisa Clínica e Incorporação Tecnológica Instituto Nacional de (BR) Dr. Clarissa Baldotto [1] 
Hospital Mãe de Deus (BR) Dr. Fabiana Viola [1] 
Hospital Albert Einstein (BR) Dr. Suzana Malheiros [1] 
Monash Medical Centre (AU) Dr. Jason Lickliter [1] 
Launceston General Hospital (AU) Dr. Stanislaw Gauden [1] 
Prince of Songkhla University Hospital (TH) Dr. Arunee Dechaphunkul [1] 
King Chulalongkorn Memorial Hospital (TH) Dr. Iyavut Thaipisuttikul [1] 
Waikato Hospital, Regional Cancer Centre (NZ) Dr. Ziad Thotathil [1] 
Tri-Service General Hospital (TW) Dr. Hsin-I Ma [1] 
Taichung Veterans General Hospital (TW) Dr. Wen-Yu Cheng [1] 
Chi Mei Medical Center (TW) Dr. Chin-Hong Chang [1] 
Instituto Oncologico Miraflores (PE) Dr. Fernando Salas [1] 
Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie (CH) Dr. Pierre-Yves Dietrich [1] 
Chefarzt Medizinische Onkologie  (CH) Dr. Christoph Mamot [1] 
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Dana Farber Cancer Institute (USA) Dr. Lakshmi Nayak [0*] 
Sahyadri Speciality Hospital (IN) Dr. Shona Nag [0*] 
 
*No patients were enrolled, however patients transferred from other sites and were treated on study at this 
institution. 
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